A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children’s Oncology Group
Denosumab was well-tolerated with anticipated side effects and pharmacokinetic and pharmacodynamic parameters but had insufficient activity for further development in osteosarcoma.
Authors
- Steven G. DuBois (ORCID: https://orcid.org/0000-0003-0882-738X)
- Alexander J. Chou (ORCID: https://orcid.org/0000-0002-7926-3326)
- Heike Elisabeth Daldrup-Link (ORCID: https://orcid.org/0000-0002-4929-819X)
- Holcombe E. Grier (ORCID: https://orcid.org/0009-0001-7701-2304)
- Joel M. Reid (ORCID: https://orcid.org/0000-0003-2872-3123)
- Michael S. Isakoff (ORCID: https://orcid.org/0000-0003-4790-9919)
- Damon R. Reed (ORCID: https://orcid.org/0000-0002-8238-2465)
- Laura Hall
- Richard Görlick (ORCID: https://orcid.org/0000-0001-8995-2929)
- Lisa M. Kopp (ORCID: https://orcid.org/0000-0002-3412-4189)
- R. Lor Randall (ORCID: https://orcid.org/0000-0002-3660-774X)
- Katherine A. Janeway (ORCID: https://orcid.org/0000-0001-6000-3594)
- Pooja Hingorani (ORCID: https://orcid.org/0000-0002-4772-7456)
- Jill L. Lee
- John J. Doski (ORCID: https://orcid.org/0000-0003-4417-0696)
- Mark Krailo (ORCID: https://orcid.org/0000-0002-7608-0698)
- Allen Buxton
Institutions
- Children's Oncology Group (CH)
- University of Southern California (US)
- University of Minnesota (US)
- Lucile Packard Children's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Arizona (US)
- The University of Texas at San Antonio Health Science Center (US)
- Cornell University (US)
- AbbVie (United States) (US)
- Kettering University (US)
- Urology San Antonio (US)
- Monroe Carell Jr. Children's Hospital (US)
- Connecticut Children's Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Cancer Clinic (US)
- Mayo Clinic in Arizona (US)
- National Public Health Institute of Liberia (LR)
- California Library Association (US)
- University of California Davis Medical Center (US)
- Tanabe Research Laboratories (US)
- Minnesota Oncology (US)
- University of Minnesota Children's Hospital (US)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- Weill Cornell Medicine (US)
- University of California, Davis (US)
- Vanderbilt University Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2885
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00